EASD: Superior Efficacy-Dose Ratio for Lantus® over Detemir
Seventy-six percent higher dose of insulin detemir needed to achieve similar, well tolerated glycemic control versus Lantus®.
Advertisement
Sanofi-aventis announced results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus® (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir.
In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, patients taking Lantus® required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7% without symptomatic hypoglycaemia compared to patients on insulin detemir, who received 76.5 units -- an increase of 76% (p<0.001). Despite lower doses of insulin in the glargine group, Lantus® once-daily and insulin detemir twice-daily resulted in similar improvements in glycemic control (HbA1c) and a similar risk of hypoglycaemia (primary endpoint: 27.5% vs 25.6%, p=0.52). Patients in the Lantus® arm of the study also achieved significantly lower fasting blood glucose (-63.1 mg/dL Lantus® vs. -57.7 mg/dL, p<0.001).
Study Investigator Hertzel Gerstein, Professor of Diabetes Medicine, Faculty of health sciences, Hamilton, Canada, stated that, "This study demonstrated that for insulin-naïve patients with Type 2 diabetes, initiating insulin therapy with once-daily glargine achieved the same glycemic control as twice-daily detemir, with somewhat more weight gain, but lower insulin doses."
In the study, patients taking Lantus® once-daily reported a significantly greater treatment satisfaction over insulin detemir twice-daily, with over 50% less drop-outs (4.6% vs. 10.1%, p=0.001). Discontinuations in patients taking insulin detemir were primarily due to adverse events, including skin reactions. Whilst a similar rate of overall hypoglycaemia and nocturnal hypoglycaemia was observed in both arms, patients on Lantus® once-daily experienced less daytime hypoglycaemia as compared to insulin detemir (1.06 vs. 1.64 events per patient year, p=0.046). Patients on insulin detemir experienced less weight gain (0.6 vs. 1.4 kg, difference 0.77 kg, p<0.001).
The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.